Monday 05 October 18:30
Long term benefits of a holistic approach on dyslipidaemia management; today for a greater future.
This symposium is organised and supported by Mylan.
- Carlos Tavares Aguiar
- Alberto Zambon
Are new LDL-C goals for ACS achievable in real life? How Registries could help?
Fenofibrate and EPA: Are they equal when it comes to hypertriglyceridemia management?
Low-dosage red yeast rice supplementation in cholesterol control: review and expert opinion by ILEP
Tuesday 06 October 12:30
FCS and me: Living with a rare lipid disorder and the APPROACH to treatment
This symposium is organised and supported by Akcea.
- Pedro Valdivielso Felices
A treatment in context: clinician perspectives on volanesorsen from real word experience
Expert and patient insights: interactive Q&A, summary and closing remarks
Living with FCS: through the eyes of a patient
Treatment of FCS with an antisense oligonucleotide (volanesorsen) and the APPROACH study
Welcome and introduction
Wednesday 07 October 14:30
Targeting PCSK9: translating ESC/EAS guidelines to the real world
This symposium is organised and supported by Amgen.
- François Mach
How did the ESC/EAS guidelines change my practice?
Introduction. Targeting PCSK9: from bench to real world
LDL-C reduction: earlier, lower, better!
Lessons from the DA VINCI study
PCSK9 inhibition: what do we know so far?
PCSK9 inhibitors; what can we learn from 5 years of real-world experience?
LIVE Panel discussion: with a focus on very-high risk patients
Conclusions and take- home messages
Wednesday 07 October 16:00
Add on to take back control: Combining lipid lowering therapies for the management of patients at risk
This symposium is organised and supported by Daiichi-Sankyo.
- Alberico L. Catapano
Welcome and introduction
New LDL-C goals: Practical implications for the management of patients with residual risk
Combination of lipid lowering therapies: Evidence from Mendelian randomization studies
On the horizon: Novel options for the combination of LDL-C lowering therapies
Panel discussion & Conclusion
Wednesday 07 October 13:15
The Changing Face of HoFH
This symposium is organised and supported by Amryt.
- Marcello Arca
Finding HoFH – is a rare disease hard to find?
Introduction – Chair
Lomitapide effectiveness and tolerability in patients with homozygous familial hypercholesterolaemia – updated data from an Italian cohort
Lomitapide hepatic data in HoFH – a hepatologists perspective